한글목차

Cerevel Therapeutics는 초기 및 후기 파킨슨병 치료제로 타바파돈을 개발하고 있습니다. 타바파돈은 1일 1회 경구용 생물학적 이용 가능한 부분 작용제로 합리적으로 설계되었으며, 도파민 D1/D5 수용체 아형을 선택적으로 표적화하여 유의미한 운동 활성과 바람직한 안전성 프로파일의 균형을 맞추고 있습니다.

Cerevel은 현재 타바파돈의 파킨슨병 단독요법(초기) 및 병용요법(후기)에 대한 임상 3상 시험인 TEMPO-1, TEMPO-2, TEMPO-3을 진행하고 있습니다. 파킨슨병에 대한 단독요법(초기) 및 병용요법(후기) 임상 3상을 진행하고 있습니다. 세레벨은 TEMPO-4라는 이름의 오픈 라벨 연장 임상시험도 진행 중이며, TEMPO-3의 데이터는 2024년 중반, TEMPO-1과 TEMPO-2의 데이터는 2024년 후반에 나올 것으로 예상하고 있습니다.

타바파돈은 직접 운동 경로를 특이적으로 활성화하여 낮 동안의 진정(졸음), 충동 조절 저하, 환각을 포함한 정신병적 증상의 위험 등 도파민을 비선택적으로 자극하는 약물의 전형적인 부작용을 최소화하면서 운동 효과를 촉진할 수 있습니다. 또한 이 약은 운동 효과를 극대화하는 수준으로 D1/D5 수용체 아형을 활성화하는 동시에 운동 효과를 극대화하는 수준으로 D1/D5 수용체 아형을 활성화하도록 설계되어 풀아고니스트에 의한 장시간의 수용체 과흥분 및 탈감작을 억제하고 이상운동증과 '꺼짐' 시간을 악화시킬 수 있습니다.

앞으로 몇 년동안 파킨슨병 시장 시나리오는 전 세계적으로 광범위한 조사와 의료비 지출 증가로 인해 변화할 것입니다. 각 업체들은 질병을 치료/개선하기 위한 새로운 접근법에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, 타바파돈의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 다른 파킨슨병 치료제들이 타바파돈과 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발 신약이 출시되면 시장에 큰 영향을 미칠 것으로 예상됩니다.

이 보고서는 주요 7개국의 파킨슨병 치료제 타바파돈(Tabapadone) 시장에 대해 조사했으며, 시장 개요, 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.

목차

제1장 보고서 서론

제2장 파킨슨병에서의 타바파돈 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신흥 치료법)

제5장 타바파돈 시장 평가

• 파킨슨병용 타바파돈 시장 전망
• 주요 7개국 분석
  • 주요 7개국의 파킨슨병 치료제 타바파돈 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

제12장 보고서 구입 옵션

영문목차

"Tavapadon Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about tavapadon for Parkinson's disease in the seven major markets. A detailed picture of the tavapadon for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the tavapadon for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the tavapadon market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.

Drug Summary:

Cerevel Therapeutics is developing tavapadon to treat both early and late-stage Parkinson's disease. Tavapadon was rationally designed as an orally-bioavailable, once-daily partial agonist that selectively targets dopamine D1/D5 receptor subtypes to balance meaningful motor activity with a favourable safety profile.

It has the potential to be used as both, a monotherapy for early-stage Parkinson's disease and as adjunctive therapy for late-stage Parkinson's disease. Cerevel is currently conducting Phase III trials of tavapadon, known as TEMPO-1, TEMPO-2, and TEMPO-3, as monotherapy (early-stage) and adjunctive (late-stage) in Parkinson's disease. It is also conducting an open-label extension trial, known as TEMPO-4. Cerevel expects data from the TEMPO-3 trial in mid-year 2024 and TEMPO-1 and TEMPO-2 in the second half of 2024.

Mechanism of Action

Tavapadon differentially activates the direct motor pathway, potentially driving motor benefit while minimizing side effects typical of drugs that non-selectively stimulate dopamine, such as daytime sedation, or somnolence, compromised impulse control, and risk of psychotic symptoms including hallucinations. The drug is also designed to activate the D1/D5 receptor subtypes at levels that maximize motor benefit while reducing the prolonged receptor overexcitation and desensitization caused by full agonists, leading to dyskinesias and exacerbation of "off" time.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the tavapadon description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
• Elaborated details on tavapadon regulatory milestones and other development activities have been provided in this report.
• The report also highlights the tavapadon research and development activities in Parkinson's disease across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around tavapadon.
• The report contains forecasted sales of tavapadon for Parkinson's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
• The report also features the SWOT analysis with analyst views for tavapadon in Parkinson's disease.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Tavapadon Analytical Perspective by DelveInsight

• In-depth Tavapadon Market Assessment

This report provides a detailed market assessment of tavapadon for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• Tavapadon Clinical Assessment

The report provides the clinical trials information of tavapadon for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence tavapadon dominance.
• Other emerging products for Parkinson's disease are expected to give tough market competition to tavapadon and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of tavapadon in Parkinson's disease.
• Our in-depth analysis of the forecasted sales data of tavapadon from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the tavapadon in Parkinson's disease.

Key Questions:

• What is the product type, route of administration and mechanism of action of tavapadon?
• What is the clinical trial status of the study related to tavapadon in Parkinson's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the tavapadon development?
• What are the key designations that have been granted to tavapadon for Parkinson's disease?
• What is the forecasted market scenario of tavapadon for Parkinson's disease?
• What are the forecasted sales of tavapadon in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to tavapadon for Parkinson's disease?
• Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?

Table of Contents

1. Report Introduction

2. Tavapadon Overview in Parkinson's disease

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and Efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Tavapadon Market Assessment

• 5.1. Market Outlook of Tavapadon in Parkinson's disease
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Tavapadon in the 7MM for Parkinson's disease
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Tavapadon in the United States for Parkinson's disease
  • 5.3.2. Market Size of Tavapadon in Germany for Parkinson's disease
  • 5.3.3. Market Size of Tavapadon in France for Parkinson's disease
  • 5.3.4. Market Size of Tavapadon in Italy for Parkinson's disease
  • 5.3.5. Market Size of Tavapadon in Spain for Parkinson's disease
  • 5.3.6. Market Size of Tavapadon in the United Kingdom for Parkinson's disease
  • 5.3.7. Market Size of Tavapadon in Japan for Parkinson's disease

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options